Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00138138 · ClinicalTrials.gov registry record · Phase 2
Psychostimulants for Fatigue in Prostate Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00138138: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00138138 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00138138, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
Fatigue is one of the most common symptoms of prostate cancer. Fatigue is a lack of energy that makes it harder to do the things you normally do every day. Some symptoms of fatigue are: * feeling tired and/or weak; * having less interest in activities; * having trouble concentrating; * feeling "down"; * feeling exhausted for no clear reason. There are not many drugs that are helpful in treating fatigue. However, one group of medications does seem to be useful. In this study, we, the investigators at Memorial Sloan-Kettering Cancer Center, will be using a psychostimulant called Ritalin. The aim of this study is to see if this drug is helpful in treating fatigue in prostate cancer. We are also studying the side effects of this medication.
Interventions
- DRUG Ritalin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2002-10 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00138138
The ClinicalTrials.gov registry entry for NCT00138138 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ritalin is the first listed.
NCT00138138 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00138138 about?
NCT00138138 is a clinical study titled "Psychostimulants for Fatigue in Prostate Cancer". Fatigue is one of the most common symptoms of prostate cancer. Fatigue is a lack of energy that makes it harder to do the things you normally do every day. Some symptoms of fatigue are: * feeling tired and/or weak; * having less interest in activities; * having trouble concentrating; * feeling "dow...
What is the current status of trial NCT00138138?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2002-10. Estimated completion is 2006-08.
What interventions are being tested in trial NCT00138138?
The interventions under investigation include: Ritalin (DRUG).
Who is sponsoring clinical trial NCT00138138?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.